Business Context and Reporting Period
Cytosorbents Corp (CTS) filed a Form 8-K on March 25, 2025, announcing a material restatement of previously issued financial statements. The filing addresses errors identified during the year ended December 31, 2024, affecting the audited 2023 Annual Report and interim quarterly reports for 2023 and 2024.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the nature of accounting errors rather than current period performance metrics.
Material Changes and Restatement Details
The Company determined that prior financial statements should no longer be relied upon due to the following misstatements:
- Inventory Overstatement: Caused by a clerical error.
- Stock-Based Compensation Understatement: Errors in the application of accounting policy for Restricted Stock Units (RSUs). The Company incorrectly adjusted compensation expense based on fair value at the vesting date rather than the grant date. Additionally, a portion of the expense was incorrectly recorded against accrued liabilities instead of additional paid-in capital and accumulated deficit.
These errors impact the consolidated financial statements for the year ended December 31, 2023, and the first three quarters of fiscal years 2023 and 2024.
Outlook, Risks, and Management Commentary
Management and the Audit Committee have discussed these matters with the independent registered public accounting firm. The Company stated that the 2024 Annual Report, once filed, will contain restated consolidated financial statements that may be relied upon. The filing includes standard cautionary language regarding forward-looking statements, noting inherent risks and uncertainties related to operations and controls.
Investor Verification Checklist
- Verify the magnitude of the inventory overstatement and its impact on the balance sheet.
- Confirm the corrected stock-based compensation expense and its effect on net income and accumulated deficit.
- Review the upcoming 2024 Annual Report (Form 10-K) for the restated financial figures.
- Assess the effectiveness of internal controls following the identification of clerical and policy application errors.